EARS Auris Medical Holding Ltd.

1.91
-0.11  -5%
Previous Close 2.02
Open 2.02
Price To Book 0.7
Market Cap 6,308,031
Shares 3,302,634
Volume 163,050
Short Ratio
Av. Daily Volume 123,989
Stock charts supplied by TradingView

NewsSee all news

  1. Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain

    Hamilton, Bermuda, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and

  2. Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program

    Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology

  3. Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine

    Hamilton, Bermuda, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology

  4. Auris Medical Announces Appointment of New Chief Financial Officer

    Hamilton, Bermuda, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology

  5. Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs

    Hamilton, Bermuda, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Open label safety trial data released April 24, 2017 and May 9, 2017.
Keyzilen (AM-101) - AMPACT open-label
Acute inner ear tinnitus
Phase 3 HEALOS trial did not meet primary endpoint - November 28, 2017.
AM-111 HEALOS
Acute inner ear hearing loss
Phase 3 data released March 13, 2018 - primary endpoint not met. Noted April 25, 2019 that it intends to discuss a new Phase 2/3 trial with the FDA.
Keyzilen (AM-101)
Acute inner ear tinnitus
Phase 3 ASSENT trial terminated - November 28, 2017.
AM-111 ASSENT
Acute inner ear hearing loss
Phase 2 trial (REACH) enrollment pending funding.
AM-111 REACH
Surgery-induced hearing loss
Phase 3 trial did not meet primary endpoints
AM-101 (Keyzilen) - TACTT2
Acute inner ear tinnitus
Phase 2 interim analysis due 4Q 2019 or 1Q 2020.
AM-125
Vertigo
Phase 1b data from second part of trial due 1Q 2020.
AM-201
Healthy volunteers

Latest News

  1. Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain

    Hamilton, Bermuda, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and

  2. Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program

    Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology

  3. Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine

    Hamilton, Bermuda, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology

  4. Auris Medical Announces Appointment of New Chief Financial Officer

    Hamilton, Bermuda, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology

  5. Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs

    Hamilton, Bermuda, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and